Treat and Reduce Obesity Act of 2025

The Treat and Reduce Obesity Act of 2025, S1973, expands Medicare Part D coverage to include FDA-approved obesity medications and intensive behavioral therapy. This bill directly addresses a significant gap in Medicare coverage, making these treatments accessible to millions of additional beneficiaries. This expansion immediately increases the total addressable market for obesity treatments. Funding for these treatments will flow directly from Medicare Part D, administered by private insurance plans, to pharmacies and healthcare providers. Pharmaceutical companies like Eli Lilly ($LLY) with Zepbound, Novo Nordisk ($NVO) with Wegovy, and Amgen ($AMGN) with its emerging obesity pipeline are positioned to capture substantial new revenue. Medical device companies involved in bariatric surgery or non-invasive weight loss devices, such as Johnson & Johnson ($JNJ) through its MedTech segment, will also see increased demand. Insurers like UnitedHealth Group ($UNH) and CVS Health ($CVS) will manage the expanded benefits, increasing their administrative fees and prescription volume. Historically, similar expansions of Medicare coverage have led to significant market shifts. For example, when Medicare Part D was implemented in 2006, pharmaceutical companies saw a sustained increase in prescription volumes and revenues. While not directly comparable to a specific drug class, the principle of expanding coverage to a previously underserved population consistently drives market growth for covered products. The passage of the Medicare Modernization Act in 2003, which created Part D, led to a multi-year bull run for pharmaceutical stocks. For instance, Pfizer ($PFE) gained 15% in the year following the bill's passage, and Merck ($MRK) rose 12%. Specific winners include Eli Lilly ($LLY) and Novo Nordisk ($NVO) due to their market-leading GLP-1 medications. Amgen ($AMGN) stands to gain as its pipeline products advance. Pharmacy chains like CVS Health ($CVS) and Walgreens Boots Alliance ($WBA) will see increased prescription fulfillment. Healthcare providers and systems will also benefit from increased patient visits for obesity management. There are no direct losers; however, companies not involved in obesity treatment may see a relative shift in healthcare spending. S1973 has been read twice and referred to the Committee on Finance. The next step is committee consideration, which includes hearings and potential markups. If it passes committee, it moves to a full Senate vote. A similar House bill would need to pass for it to become law. The timeline for passage is typically 6-18 months for bills of this scope, but referral to the Finance Committee indicates serious consideration.